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Introduction: Sorafenib, a multikinase inhibitor as a standard of care for advanced hepatocellular carcinoma, may
lead endothelial cells to an unstable state by blocking the signaling pathway of vascular endothelial growth factor
receptor, which may result in the disruption of the architecture and integrity of the microvasculature, and
eventually increase the risk of hemorrhage. Hemobilia is a relatively uncommon condition as a consequence of
hepatocellular carcinoma and its risk factors remain uncertain.
Case presentation: Here we report a unique case of hemobilia occurring in a 55-year-old Korean man with
hepatitis B virus-related hepatocellular carcinoma on Barcelona Clinic Liver Cancer advanced stage after seven days
of treatment with sorafenib. He had received prior radiation therapy. Endoscopy revealed bleeding from the major
duodenal papilla and endoscopic retrograde cholangiography revealed an amorphous filling defect throughout the
common bile duct. Blood clots were removed by balloon sweeping and a nasobiliary drainage tube was placed. No
further bleeding has been detected as of eight months after discontinuation of sorafenib.
Conclusion: Sorafenib may increase the risk of biliary bleeding in hepatocellular carcinoma patients who were
primed with irradiation, by blocking the signaling pathway of the vascular endothelial growth factor receptor.
Therefore, sorafenib should be used with caution in patients with advanced hepatocellular carcinoma, especially
when combined with radiation therapy.
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Hemobilia is a very rare manifestation of hepatocellular
carcinoma (HCC) [1]. Almost all cases occur in patients
who have accompanying bile duct invasion [2,3]; however,
the predisposing factors in these patients are uncertain. So-
rafenib, a multikinase inhibitor, is recognized as a standard
of care for advanced HCC accompanied by extrahepatic
spreading or macrovascular invasion. Recently, it was
thought that sorafenib can increase the risk of hemorrhage
by inhibiting a signaling pathway of the vascular endothe-
lial growth factor (VEGF) receptor [4]. Bleeding events,
which can be caused by anti-VEGF signaling therapy, such
as sorafenib, sunitinib or bevacizumab, include epistaxis,* Correspondence: ihsong21@dankook.ac.kr
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unless otherwise stated.hemoptysis, gastrointestinal bleeding, vaginal bleeding and
brain hemorrhage [5]. Epistaxis is the most commonly re-
ported bleeding episode which is self-limited to dose ad-
justment; however, gastrointestinal bleedings inclusive of
pulmonary or intracranial hemorrhage are reported rela-
tively less often but may be fatal [4,6]. Here, we report a
case of hemobilia occurring in a patient with advanced
HCC after administration of sorafenib, with a review of the
literature.
Case presentation
A 55-year-old Korean man with HCC associated with liver
cirrhosis secondary to chronic hepatitis B virus infection
was admitted because of hematemesis and epigastric pain.
He had undergone five sessions of transhepatic arterial
chemoembolization therapy in the past 12 months. Three
weeks previously, he had received radiation therapy due to
bone metastasis at the level of the 11th thoracic vertebrad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ously, sorafenib was started at a dose of 400mg twice daily.
At that time, our patient’s Child-Pugh’s classification was
A and Eastern Cooperative Oncology Group performance
score was 2.
On admission, his blood pressure was 120/80mmHg
and pulse rate was 74 beats per minute. Digital rectal
examination was negative and a small amount of fresh
blood was drained via a nasogastric tube. Laboratory
data included the following: hemoglobin 15.3g/dL, platelet
26,000/mm3, total bilirubin 12.2mg/dL, albumin 4.1g/dL,
aspartate aminotransferase 192U/L, alanine aminotrans-
ferase 181U/L, alkaline phosphatase 301IU/L, gamma glu-
tamyltransferase 137U/L, amylase 58U/L, lipase 26U/L
and a prothrombin time of 16.7 seconds. Child-Pugh’s
classification was B.
Abdominal computed tomography (CT) demonstrated
a thrombus in the posterior branch of right portal vein
(Figure 1A) and dilatation of intrahepatic bile duct
(Figure 1B) adjacent to a partially lipiodolized nodule in
the portal-venous phase. Upper gastrointestinal endoscopy
showed fresh blood emerging from major duodenal papilla
(Figure 2). Endoscopic retrograde cholangiography re-
vealed an amorphous filling defect throughout the com-
mon bile duct (Figure 3A). Blood clots were removed by
balloon sweeping (Figure 3B) and a nasobiliary drainage
tube was placed.
After discontinuation of sorafenib administration, with
a regular irrigation of saline via nasobiliary tube, our pa-
tient became hemodynamically stable and total bilirubin
level decreased to 4.6mg/dL. He was discharged and no
further bleeding has been detected as of eight months
after the episode.
Discussion
Hemobilia is a relatively uncommon cause of gastro-
intestinal bleeding and is usually associated with trauma,Figure 1 Computed tomography. (A) A thrombus was noted in the post
duct (arrow) adjacent to a partially lipiodolized nodule suggested direct inv
portal-venous phase.cholelithiasis, acalculous inflammatory diseases, vascular
disorders and tumors. When HCC invades the biliary
tree, hemobilia can occur due to rupture of the tumor
into the biliary system [2]. In our present case, tumor in-
vasion into the intrahepatic bile duct was suspicious, but
not definite on the abdominal imaging scan.
Kojiro et al. [3] found hemobilia occurring in 5 (21%)
of 24 HCC cases with tumor growth within bile ducts;
however, it is unclear how many cases of hemobilia de-
velop in patients with HCC and what the predisposing
factors are. Verset et al. [7] has reported two cases of
fatal hemobilia in patients with advanced HCC on the
second and seventh day after sorafenib therapy and our
present patient was also admitted with hematemesis on
the seventh day after sorafenib administration. Adverse
events of VEGF receptor-targeted agents relevant to
bleeding have been usually reported to occur early in the
course of treatment [8,9]. Sorafenib administration itself
may be the potential cause of the development of gastro-
intestinal bleeding presented as hemobilia in our patient.
Sorafenib is a small molecule inhibitor of multiple
tyrosine kinase receptors that regulates cell proliferation
and angiogenesis. It is now the standard of care for pa-
tients with advanced-stage HCC with macrovascular in-
vasion or extrahepatic spread [5,10]. Rash, exfoliative
dermatitis, hand-foot skin reaction, diarrhea, fatigue and
hypertension are common adverse effects of sorafenib
[4,11]. Although there are still some debates whether so-
rafenib may increase the risk of bleeding, a recent meta-
analysis showed a significant two-times increased risk of
a bleeding event in cancer patients treated with sorafe-
nib or sunitinib [12]. These bleeding events can be
thought of as being associated with the aberrant disrup-
tion of VEGF signaling involved in mechanisms related
to vascularization and coagulation. VEGF stimulates
endothelial cell proliferation as well as promotes endo-
thelial cell survival, which, consequently, helps maintainerior branch of right portal vein (arrow). (B) Dilatation of intrahepatic
asion of the tumor into the surrounding intrahepatic duct in the
Figure 2 Upper gastrointestinal endoscopy. Fresh blood was
gushing from major duodenal papilla.
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[11]. Therefore, inhibition of VEGF signaling can de-
crease the renewal capacity of the endothelial cell in re-
sponse to trauma, which causes endothelial dysfunction,
and eventually increases the risk of hemorrhage. Fur-
thermore, it is considered that the weakening of the
walls of major vessels by tumor erosion, necrosis, cavita-
tion or other concurrent pathological conditions are alsoFigure 3 Endoscopic retrograde cholangiography. (A) An amorphous f
(B) Blood clots were removed by balloon sweeping.likely to play a central role in causing hemorrhage in pa-
tients on anti-VEGF therapy [4]. In the present case, ab-
dominal CT performed six weeks prior to the bleeding
event showed suspicious tumor invasion into the intra-
hepatic duct adjacent to the primary nodule; however, at
that time, there was no evidence of bleeding radiologic-
ally as well as clinically. Hemobilia was found on the
seventh day after sorafenib therapy began and the bleed-
ing stopped with conservative management with sorafe-
nib discontinuation. It was thought that the tumor had
weakened the wall of the portal vein and sorafenib pre-
cipitated bleeding into the bile duct by blocking VEGF
signaling.
Hui et al. [13] reported that the risk of bleeding with
sunitinib, one of the VEGF receptor tyrosine kinase in-
hibitors, was higher in patients with nasopharyngeal car-
cinoma who received prior high-dose radiation therapy
than those who did not. Irradiation causes damage to
the endothelial cells in the capillary network and nega-
tively influences the subsequent vascular repair process
[14], and also enhances sensitivity of endothelial cells to
anti-VEGF therapy [15]. In the present case, the patient
received radiation therapy for two weeks prior to sorafe-
nib administration. Previous radiation therapy may be
another factor contributing to increased risk of bleeding
in HCC patients on anti-VEGF therapy.Conclusions
Sorafenib may increase the risk of bleeding in HCC pa-
tients who were primed with irradiation, by disruption
of the architecture and integrity of the microvasculature,
which may result from blocking of the signaling pathway
of the VEGF receptor. Therefore, sorafenib should beilling defect was seen throughout the common bile duct (arrows).
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cially when combined with radiation therapy.
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